id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-D-0187-0031,FDA,FDA-2000-D-0187,Ref 4 Mace KE et al - MMWR 2017 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:02:06Z,,0,0,09000064846f6952
FDA-2000-D-0187-0030,FDA,FDA-2000-D-0187,Ref 3 - OBrien SF - Transfusion medicine reviews 2015 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:01:54Z,,0,0,09000064846f6951
FDA-2000-D-0187-0043,FDA,FDA-2000-D-0187,"Ref 15 FDA BPAC Transcripts 111609 
Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria",Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:05:11Z,,0,0,09000064846f69b0
FDA-2000-D-0187-0026,FDA,FDA-2000-D-0187,Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Other,Guidance,2020-06-17T04:00:00Z,2020,6,2020-06-17T04:00:00Z,,2022-12-08T15:47:25Z,,0,0,09000064846f6586
FDA-2000-D-0187-0027,FDA,FDA-2000-D-0187,Reference List Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:00:39Z,,0,0,09000064846f658e
FDA-2000-D-0187-0039,FDA,FDA-2000-D-0187,"Ref 11 Doolan D L et al Acquired immunity to malaria 
Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria",Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:04:15Z,,0,0,09000064846f69ac
FDA-2000-D-0187-0033,FDA,FDA-2000-D-0187,Ref 5 - Mace KE et al - MMWR 2018Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:02:37Z,,0,0,09000064846f697e
FDA-2000-D-0187-0036,FDA,FDA-2000-D-0187,Ref 8 - Reesink et al - Transfusion 2010 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:03:23Z,,0,0,09000064846f6981
FDA-2000-D-0187-0041,FDA,FDA-2000-D-0187,Ref 13 FDA Workshop Testing for malarial infections in blood donors July 12 2006 FDA Blood Products Advisory Committee Testing for malarial infections in blood donors July 13 2006,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:04:50Z,,0,0,09000064846f69ae
FDA-2000-D-0187-0029,FDA,FDA-2000-D-0187,Ref 2 - Mungai M et al - NEJM 2001 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:01:44Z,,0,0,09000064846f6950
FDA-2000-D-0187-0035,FDA,FDA-2000-D-0187,Ref 7 Spencer B et al Risk for malaria in United States donors deferred for travel to malaria endemic areas Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:03:14Z,,0,0,09000064846f6980
FDA-2000-D-0187-0032,FDA,FDA-2000-D-0187,Ref 5 - Mace KE et al - MMWR 2018 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:02:16Z,,0,0,09000064846f6953
FDA-2000-D-0187-0034,FDA,FDA-2000-D-0187,Ref 6 - Mace KE et al - MMWR 2019 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:03:00Z,,0,0,09000064846f697f
FDA-2000-D-0187-0037,FDA,FDA-2000-D-0187,Ref 9 - Spenser B et al - Transfusion Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:03:35Z,,0,0,09000064846f6982
FDA-2000-D-0187-0042,FDA,FDA-2000-D-0187,"Ref 14 FDA Blood Products Advisory Committee - Sept 2008 
Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria",Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:05:00Z,,0,0,09000064846f69af
FDA-2000-D-0187-0038,FDA,FDA-2000-D-0187,"Ref 10 Liljander A et al Influences of intermittent preventive treatment and persistent multiclonal Plasmodium falciparum in-1 
Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria",Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:03:48Z,,0,0,09000064846f6983
FDA-2000-D-0187-0028,FDA,FDA-2000-D-0187,Ref 1 - Katz LM & Spenser BR - AABB Press 2019 Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria,Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:00:59Z,,0,0,09000064846f694f
FDA-2000-D-0187-0025,FDA,FDA-2000-D-0187,"Revised Recommendations To Reduce the Risk of Transfusion-Transmitted
Malaria; Guidance for Industry; Availability",Notice,Notice of Availability,2020-06-17T04:00:00Z,2020,6,2020-06-17T04:00:00Z,,2020-06-17T13:13:25Z,2020-13066,0,0,09000064846f5e19
FDA-2000-D-0187-0040,FDA,FDA-2000-D-0187,"Ref 12 - Nguyen ML et al - Transfusion 2013 
Re: Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria",Supporting & Related Material,Background Material,2020-06-17T04:00:00Z,2020,6,,,2020-06-17T15:04:26Z,,0,0,09000064846f69ad
FDA-2000-D-0187-0024,FDA,FDA-2000-D-0187,Revised Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria Guidance for Industry,Other,Guidance,2020-04-03T04:00:00Z,2020,4,2020-04-03T04:00:00Z,,2024-11-06T23:34:52Z,,1,0,0900006484485685